Farzaneh Ebrahimy1, Mahrokh Dolatian1, Fariborz Moatar2, Hamid Alavi Majd3. 1. Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Pharmacognosy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. 3. Department of Biostatistics, Faculty of Paramedicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract
INTRODUCTION: This study aimed to determine and compare the effects of garlic tablets (Garcin(®)) and fluconazole on Candida vaginitis in women who presented to a health centre in Koohdasht, Iran, from August 2011 to March 2012. METHODS: The clinical trial was conducted on 110 married women (aged 18-44 years) who had complaints of itching or a burning sensation in the vaginal area. Candida vaginitis was diagnosed by pH measurement of vaginal secretions, direct microscopic evaluation and Sabouraud dextrose agar cultures of the vaginal discharge. On confirmation of diagnosis, the patients were randomly divided into two groups (n = 55). One group received 1,500 mg of Garcin tablets daily and the other received fluconazole tablets 150 mg daily, over a period of seven days. Four to seven days after the completion of treatment, patients were examined for treatment response and possible side effects. RESULTS: Complaints related to the disease improved by about 44% in the Garcin group and 63.5% in the fluconazole group (p < 0.05). The overall symptoms of the disease (i.e. redness of vulva and vagina, cheesy discharge, pustulopapular lesions and abnormal cervix) improved by about 60% in the Garcin group and 71.2% in the fluconazole group (p > 0.05). Results of microscopic evaluation and vaginal discharge culture showed significant differences before and after intervention in both groups (p < 0.05). CONCLUSION: The present study shows that Garcin tablets could be a suitable alternative to fluconazole for the treatment of Candida vaginitis.
RCT Entities:
INTRODUCTION: This study aimed to determine and compare the effects of garlic tablets (Garcin(®)) and fluconazole on Candida vaginitis in women who presented to a health centre in Koohdasht, Iran, from August 2011 to March 2012. METHODS: The clinical trial was conducted on 110 married women (aged 18-44 years) who had complaints of itching or a burning sensation in the vaginal area. Candida vaginitis was diagnosed by pH measurement of vaginal secretions, direct microscopic evaluation and Sabouraud dextrose agar cultures of the vaginal discharge. On confirmation of diagnosis, the patients were randomly divided into two groups (n = 55). One group received 1,500 mg of Garcin tablets daily and the other received fluconazole tablets 150 mg daily, over a period of seven days. Four to seven days after the completion of treatment, patients were examined for treatment response and possible side effects. RESULTS: Complaints related to the disease improved by about 44% in the Garcin group and 63.5% in the fluconazole group (p < 0.05). The overall symptoms of the disease (i.e. redness of vulva and vagina, cheesy discharge, pustulopapular lesions and abnormal cervix) improved by about 60% in the Garcin group and 71.2% in the fluconazole group (p > 0.05). Results of microscopic evaluation and vaginal discharge culture showed significant differences before and after intervention in both groups (p < 0.05). CONCLUSION: The present study shows that Garcin tablets could be a suitable alternative to fluconazole for the treatment of Candida vaginitis.
Authors: Sandra S Richter; Rudolph P Galask; Shawn A Messer; Richard J Hollis; Daniel J Diekema; Michael A Pfaller Journal: J Clin Microbiol Date: 2005-05 Impact factor: 5.948
Authors: Sameh S M Soliman; Mohammad H Semreen; Ali A El-Keblawy; Arbab Abdullah; Priya Uppuluri; Ashraf S Ibrahim Journal: BMC Complement Altern Med Date: 2017-05-08 Impact factor: 3.659
Authors: Antonio Sorlozano-Puerto; Maria Albertuz-Crespo; Isaac Lopez-Machado; Lidia Gil-Martinez; Juan Jose Ariza-Romero; Alba Maroto-Tello; Alberto Baños-Arjona; Jose Gutierrez-Fernandez Journal: Pharmaceuticals (Basel) Date: 2020-12-29